Patients who stopped taking Vir Biotechnology’s experimental hepatitis delta therapy continued to suppress the virus, a result that researchers view as an early indicator of a potential functional cure.
The finding emerged from a phase 2 study and adds significant weight to the company’s broader clinical program targeting chronic hepatitis delta, a severe and difficult-to-treat liver disease.
Chronic hepatitis delta affects millions of people worldwide and has long resisted efforts to develop effective therapies, making sustained viral suppression after treatment withdrawal a particularly meaningful signal.
Vir Biotechnology (VIR) disclosed the results on Sunday, pairing the phase 2 data with a separate and equally important announcement from a larger, more advanced trial.
The company’s experimental combination treatment met its primary endpoint in a phase 3 clinical trial, giving the hepatitis delta program two positive readouts in a single disclosure.
Hitting a primary goal in a phase 3 study is the standard regulatory threshold that typically precedes applications for drug approval, marking a critical step toward potential commercialization.
Together, the two data sets represent a meaningful advance for a company that has been working to establish itself as a serious player in infectious disease treatment following setbacks in other programs.
Analysts tracking VIR have noted that a credible hepatitis delta program could redefine the company’s commercial prospects, given the lack of widely approved modern therapies for the condition.
The combination approach tested in the trials reflects a broader industry trend toward pairing antiviral mechanisms to attack persistent infections from multiple angles simultaneously.
If the phase 2 signal of post-treatment viral suppression holds in larger studies, it would distinguish Vir’s therapy from treatments that require indefinite use to maintain effect.
Sustained suppression after stopping a drug is a benchmark that researchers in viral hepatitis often describe as the closest available proxy for a functional cure in chronic infections.
The company has not yet announced a regulatory filing timeline, but the convergence of positive phase 2 and phase 3 data is expected to accelerate internal discussions about next steps with health authorities.
